Contact Information: Company Contact: Delcath Systems, Inc. Richard Taney (212) 489-2100 Investor Relations Contact: Strategic Growth International, Inc. Richard E. Cooper (212) 838-1444
Delcath Systems to Present at the 28th Annual Canaccord Adams Global Growth Conference
| Source: Delcath Systems, Inc.
NEW YORK, NY--(Marketwire - August 7, 2008) - Delcath Systems, Inc. (NASDAQ : DCTH ) today
announced that Richard L. Taney, President and CEO of Delcath Systems,
Inc., will present at the 28th Annual Canaccord Adams Global Growth
Conference on Tuesday, August 12th, 2008 at 10:30 AM EDT. The conference
will be held at the Intercontinental Hotel in Boston, Massachusetts from
August 12th through 14th, 2008. The Canaccord Adams Global Growth
Conference has continuously brought together high-quality institutional
investors with some of the best small- to mid-cap companies in the
Technology, Life Sciences, Industrial Growth, and Consumer sectors.
Mr. Taney's presentation will be webcast live and available for replay via
the following web address:
http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=DCTH&item_id=1887787.
It will also be archived on Delcath's website at www.delcath.com.
About Delcath Systems, Inc.
Delcath Systems, Inc. is a medical technology company specializing in
cancer treatment. The Company has developed a proprietary, patented system
which will improve the efficacy of cancer treatment while reducing the
considerable, systemic side-effects of chemotherapy. Delcath's novel drug
delivery platform is capable of delivering anti-cancer drugs at very high
doses to a specific organ or region of the body while preventing these high
doses of drug from entering the patient's bloodstream. The Company is
currently enrolling patients in Phase III and Phase II clinical studies for
the treatment of liver cancers using high doses of melphalan. The
Company's intellectual property portfolio consists of twenty-eight patents
on a worldwide basis including the U.S., Europe, Asia and Canada. For more
information, please visit the Company's website at www.delcath.com.
The Private Securities Litigation Reform Act of 1995 provides a safe harbor
for forward-looking statements made by the Company or on its behalf. This
news release contains forward-looking statements, which are subject to
certain risks and uncertainties that can cause actual results to differ
materially from those described. Factors that may cause such differences
include, but are not limited to, uncertainties relating to our ability to
successfully complete Phase III clinical trials and secure regulatory
approval of our current or future drug-delivery system and uncertainties
regarding our ability to obtain financial and other resources for any
research, development and commercialization activities. These factors, and
others, are discussed from time to time in our filings with the Securities
and Exchange Commission. You should not place undue reliance on these
forward-looking statements, which speak only as of the date they are made.
We undertake no obligation to publicly update or revise these
forward-looking statements to reflect events or circumstances after the
date they are made.